nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—CYP3A4—bone cancer	0.652	1	CbGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—MST1R—bone cancer	0.0111	0.113	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—MST1R—bone cancer	0.0104	0.106	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—MST1R—bone cancer	0.00543	0.0553	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptors—NR1I2—bone cancer	0.0043	0.0438	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptors—NR1I2—bone cancer	0.00404	0.0411	CbGpPWpGaD
Bexarotene—RXRA—Liver X Receptor Pathway—CYP3A4—bone cancer	0.00358	0.0364	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.0034	0.0346	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00319	0.0325	CbGpPWpGaD
Bexarotene—RXRA—Farnesoid X Receptor  Pathway—CYP3A4—bone cancer	0.00214	0.0218	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—NR1I2—bone cancer	0.00211	0.0214	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—ZNF77—bone cancer	0.00173	0.0176	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00166	0.0169	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—ZNF77—bone cancer	0.00163	0.0166	CbGpPWpGaD
Bexarotene—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00159	0.0162	CbGpPWpGaD
Bexarotene—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00152	0.0155	CbGpPWpGaD
Bexarotene—RXRA—The citric acid (TCA) cycle and respiratory electron transport—NDUFA12—bone cancer	0.00146	0.0149	CbGpPWpGaD
Bexarotene—RXRA—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00141	0.0144	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—MET—bone cancer	0.00136	0.0138	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—MET—bone cancer	0.00128	0.013	CbGpPWpGaD
Bexarotene—RXRA—Orphan transporters—TUBB4B—bone cancer	0.00115	0.0118	CbGpPWpGaD
Bexarotene—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00105	0.0107	CbGpPWpGaD
Bexarotene—RXRA—PPAR Alpha Pathway—CDK4—bone cancer	0.00103	0.0105	CbGpPWpGaD
Bexarotene—RXRA—Orphan transporters—TUBB2A—bone cancer	0.000997	0.0101	CbGpPWpGaD
Bexarotene—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000987	0.01	CbGpPWpGaD
Bexarotene—RXRG—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000884	0.009	CbGpPWpGaD
Bexarotene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000859	0.00875	CbGpPWpGaD
Bexarotene—RXRA—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000854	0.00869	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—ZNF77—bone cancer	0.000849	0.00865	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—ZNF77—bone cancer	0.000834	0.0085	CbGpPWpGaD
Bexarotene—RXRB—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000831	0.00847	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—ZNF77—bone cancer	0.000785	0.00799	CbGpPWpGaD
Bexarotene—RXRG—Regulation of Androgen receptor activity—JUN—bone cancer	0.000769	0.00783	CbGpPWpGaD
Bexarotene—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000768	0.00781	CbGpPWpGaD
Bexarotene—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000738	0.00752	CbGpPWpGaD
Bexarotene—RXRB—Regulation of Androgen receptor activity—JUN—bone cancer	0.000723	0.00736	CbGpPWpGaD
Bexarotene—RXRA—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000692	0.00705	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—EGFR—bone cancer	0.000689	0.00701	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000685	0.00697	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—MET—bone cancer	0.000666	0.00678	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—EGFR—bone cancer	0.000648	0.00659	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—NR1I2—bone cancer	0.000587	0.00597	CbGpPWpGaD
Bexarotene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000567	0.00577	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—NR1I2—bone cancer	0.000552	0.00562	CbGpPWpGaD
Bexarotene—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000527	0.00537	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—RB1—bone cancer	0.000506	0.00515	CbGpPWpGaD
Bexarotene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000502	0.00511	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00048	0.00488	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000451	0.0046	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—CDK4—bone cancer	0.000434	0.00441	CbGpPWpGaD
Bexarotene—RXRA—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000433	0.00441	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—ZNF77—bone cancer	0.000409	0.00416	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000408	0.00415	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—FUS—bone cancer	0.000407	0.00415	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—FUS—bone cancer	0.000383	0.0039	CbGpPWpGaD
Bexarotene—RXRA—Regulation of Androgen receptor activity—JUN—bone cancer	0.000377	0.00383	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000371	0.00378	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—CYP3A4—bone cancer	0.000368	0.00374	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—TGFBR2—bone cancer	0.000358	0.00365	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—GSTP1—bone cancer	0.000358	0.00365	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000338	0.00344	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—EGFR—bone cancer	0.000338	0.00344	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000333	0.0034	CbGpPWpGaD
Bexarotene—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000319	0.00324	CbGpPWpGaD
Bexarotene—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000315	0.0032	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—GSTP1—bone cancer	0.000314	0.0032	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—NR1I2—bone cancer	0.000287	0.00293	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000283	0.00288	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—NR1I2—bone cancer	0.000282	0.00288	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000282	0.00287	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—NR1I2—bone cancer	0.000266	0.0027	CbGpPWpGaD
Bexarotene—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000258	0.00263	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—RB1—bone cancer	0.000248	0.00252	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000243	0.00248	CbGpPWpGaD
Bexarotene—Angina pectoris—Doxorubicin—bone cancer	0.000231	0.000927	CcSEcCtD
Bexarotene—Epistaxis—Methotrexate—bone cancer	0.000231	0.000924	CcSEcCtD
Bexarotene—Pneumonia—Epirubicin—bone cancer	0.00023	0.000922	CcSEcCtD
Bexarotene—Bronchitis—Doxorubicin—bone cancer	0.000228	0.000915	CcSEcCtD
Bexarotene—Pancytopenia—Doxorubicin—bone cancer	0.000225	0.000904	CcSEcCtD
Bexarotene—Body temperature increased—Cisplatin—bone cancer	0.000225	0.0009	CcSEcCtD
Bexarotene—Neuropathy peripheral—Epirubicin—bone cancer	0.000224	0.000899	CcSEcCtD
Bexarotene—Jaundice—Epirubicin—bone cancer	0.000223	0.000894	CcSEcCtD
Bexarotene—Stomatitis—Epirubicin—bone cancer	0.000223	0.000894	CcSEcCtD
Bexarotene—Urinary tract infection—Epirubicin—bone cancer	0.000222	0.000891	CcSEcCtD
Bexarotene—Conjunctivitis—Epirubicin—bone cancer	0.000222	0.000891	CcSEcCtD
Bexarotene—Dysuria—Doxorubicin—bone cancer	0.000222	0.00089	CcSEcCtD
Bexarotene—Neutropenia—Doxorubicin—bone cancer	0.000222	0.00089	CcSEcCtD
Bexarotene—Haemoglobin—Methotrexate—bone cancer	0.000221	0.000884	CcSEcCtD
Bexarotene—RXRA—Metabolism—NDUFA12—bone cancer	0.00022	0.00224	CbGpPWpGaD
Bexarotene—Haemorrhage—Methotrexate—bone cancer	0.000219	0.00088	CcSEcCtD
Bexarotene—Sweating—Epirubicin—bone cancer	0.000219	0.000879	CcSEcCtD
Bexarotene—Pollakiuria—Doxorubicin—bone cancer	0.000219	0.000879	CcSEcCtD
Bexarotene—Haematuria—Epirubicin—bone cancer	0.000218	0.000874	CcSEcCtD
Bexarotene—Pharyngitis—Methotrexate—bone cancer	0.000218	0.000873	CcSEcCtD
Bexarotene—Urinary tract disorder—Methotrexate—bone cancer	0.000217	0.000869	CcSEcCtD
Bexarotene—Photosensitivity reaction—Doxorubicin—bone cancer	0.000217	0.000869	CcSEcCtD
Bexarotene—Weight increased—Doxorubicin—bone cancer	0.000216	0.000866	CcSEcCtD
Bexarotene—Epistaxis—Epirubicin—bone cancer	0.000216	0.000865	CcSEcCtD
Bexarotene—Urethral disorder—Methotrexate—bone cancer	0.000215	0.000862	CcSEcCtD
Bexarotene—Weight decreased—Doxorubicin—bone cancer	0.000215	0.000861	CcSEcCtD
Bexarotene—Sinusitis—Epirubicin—bone cancer	0.000215	0.00086	CcSEcCtD
Bexarotene—Hyperglycaemia—Doxorubicin—bone cancer	0.000214	0.000858	CcSEcCtD
Bexarotene—Pneumonia—Doxorubicin—bone cancer	0.000213	0.000853	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.00021	0.00213	CbGpPWpGaD
Bexarotene—Hypersensitivity—Cisplatin—bone cancer	0.000209	0.000839	CcSEcCtD
Bexarotene—RXRG—Gene Expression—EIF2S1—bone cancer	0.000209	0.00212	CbGpPWpGaD
Bexarotene—Neuropathy peripheral—Doxorubicin—bone cancer	0.000207	0.000832	CcSEcCtD
Bexarotene—Haemoglobin—Epirubicin—bone cancer	0.000206	0.000827	CcSEcCtD
Bexarotene—Stomatitis—Doxorubicin—bone cancer	0.000206	0.000827	CcSEcCtD
Bexarotene—Jaundice—Doxorubicin—bone cancer	0.000206	0.000827	CcSEcCtD
Bexarotene—Rhinitis—Epirubicin—bone cancer	0.000206	0.000825	CcSEcCtD
Bexarotene—Urinary tract infection—Doxorubicin—bone cancer	0.000206	0.000825	CcSEcCtD
Bexarotene—Conjunctivitis—Doxorubicin—bone cancer	0.000206	0.000825	CcSEcCtD
Bexarotene—Haemorrhage—Epirubicin—bone cancer	0.000205	0.000823	CcSEcCtD
Bexarotene—Eye disorder—Methotrexate—bone cancer	0.000205	0.000822	CcSEcCtD
Bexarotene—Tinnitus—Methotrexate—bone cancer	0.000205	0.00082	CcSEcCtD
Bexarotene—Hypoaesthesia—Epirubicin—bone cancer	0.000204	0.000819	CcSEcCtD
Bexarotene—Asthenia—Cisplatin—bone cancer	0.000204	0.000817	CcSEcCtD
Bexarotene—Pharyngitis—Epirubicin—bone cancer	0.000204	0.000817	CcSEcCtD
Bexarotene—Cardiac disorder—Methotrexate—bone cancer	0.000204	0.000816	CcSEcCtD
Bexarotene—Sweating—Doxorubicin—bone cancer	0.000203	0.000813	CcSEcCtD
Bexarotene—Urinary tract disorder—Epirubicin—bone cancer	0.000203	0.000813	CcSEcCtD
Bexarotene—Oedema peripheral—Epirubicin—bone cancer	0.000202	0.000811	CcSEcCtD
Bexarotene—Haematuria—Doxorubicin—bone cancer	0.000202	0.000809	CcSEcCtD
Bexarotene—Connective tissue disorder—Epirubicin—bone cancer	0.000202	0.000809	CcSEcCtD
Bexarotene—Urethral disorder—Epirubicin—bone cancer	0.000201	0.000807	CcSEcCtD
Bexarotene—RXRA—Gene Expression—FUS—bone cancer	0.0002	0.00203	CbGpPWpGaD
Bexarotene—Epistaxis—Doxorubicin—bone cancer	0.0002	0.0008	CcSEcCtD
Bexarotene—Angiopathy—Methotrexate—bone cancer	0.000199	0.000798	CcSEcCtD
Bexarotene—Sinusitis—Doxorubicin—bone cancer	0.000199	0.000796	CcSEcCtD
Bexarotene—Chills—Methotrexate—bone cancer	0.000197	0.000789	CcSEcCtD
Bexarotene—RXRB—Gene Expression—EIF2S1—bone cancer	0.000196	0.002	CbGpPWpGaD
Bexarotene—Diarrhoea—Cisplatin—bone cancer	0.000194	0.000779	CcSEcCtD
Bexarotene—Alopecia—Methotrexate—bone cancer	0.000194	0.000777	CcSEcCtD
Bexarotene—Eye disorder—Epirubicin—bone cancer	0.000192	0.000769	CcSEcCtD
Bexarotene—Tinnitus—Epirubicin—bone cancer	0.000191	0.000767	CcSEcCtD
Bexarotene—Erythema—Methotrexate—bone cancer	0.000191	0.000766	CcSEcCtD
Bexarotene—Malnutrition—Methotrexate—bone cancer	0.000191	0.000766	CcSEcCtD
Bexarotene—Haemoglobin—Doxorubicin—bone cancer	0.000191	0.000765	CcSEcCtD
Bexarotene—Cardiac disorder—Epirubicin—bone cancer	0.000191	0.000764	CcSEcCtD
Bexarotene—Rhinitis—Doxorubicin—bone cancer	0.00019	0.000764	CcSEcCtD
Bexarotene—Haemorrhage—Doxorubicin—bone cancer	0.00019	0.000762	CcSEcCtD
Bexarotene—Hypoaesthesia—Doxorubicin—bone cancer	0.000189	0.000758	CcSEcCtD
Bexarotene—Pharyngitis—Doxorubicin—bone cancer	0.000189	0.000756	CcSEcCtD
Bexarotene—Urinary tract disorder—Doxorubicin—bone cancer	0.000188	0.000752	CcSEcCtD
Bexarotene—Oedema peripheral—Doxorubicin—bone cancer	0.000187	0.00075	CcSEcCtD
Bexarotene—Dysgeusia—Methotrexate—bone cancer	0.000187	0.00075	CcSEcCtD
Bexarotene—Connective tissue disorder—Doxorubicin—bone cancer	0.000187	0.000748	CcSEcCtD
Bexarotene—Angiopathy—Epirubicin—bone cancer	0.000186	0.000747	CcSEcCtD
Bexarotene—Urethral disorder—Doxorubicin—bone cancer	0.000186	0.000747	CcSEcCtD
Bexarotene—Back pain—Methotrexate—bone cancer	0.000185	0.000741	CcSEcCtD
Bexarotene—Chills—Epirubicin—bone cancer	0.000184	0.000739	CcSEcCtD
Bexarotene—Arrhythmia—Epirubicin—bone cancer	0.000183	0.000735	CcSEcCtD
Bexarotene—RXRA—Metabolism—NT5C3A—bone cancer	0.000183	0.00186	CbGpPWpGaD
Bexarotene—Alopecia—Epirubicin—bone cancer	0.000181	0.000727	CcSEcCtD
Bexarotene—RXRG—Gene Expression—EZH2—bone cancer	0.000181	0.00184	CbGpPWpGaD
Bexarotene—Vomiting—Cisplatin—bone cancer	0.000181	0.000724	CcSEcCtD
Bexarotene—Rash—Cisplatin—bone cancer	0.000179	0.000718	CcSEcCtD
Bexarotene—Dermatitis—Cisplatin—bone cancer	0.000179	0.000717	CcSEcCtD
Bexarotene—Erythema—Epirubicin—bone cancer	0.000179	0.000717	CcSEcCtD
Bexarotene—Malnutrition—Epirubicin—bone cancer	0.000179	0.000717	CcSEcCtD
Bexarotene—Eye disorder—Doxorubicin—bone cancer	0.000178	0.000712	CcSEcCtD
Bexarotene—Ill-defined disorder—Methotrexate—bone cancer	0.000177	0.00071	CcSEcCtD
Bexarotene—Tinnitus—Doxorubicin—bone cancer	0.000177	0.00071	CcSEcCtD
Bexarotene—Anaemia—Methotrexate—bone cancer	0.000177	0.000708	CcSEcCtD
Bexarotene—Cardiac disorder—Doxorubicin—bone cancer	0.000176	0.000707	CcSEcCtD
Bexarotene—Flatulence—Epirubicin—bone cancer	0.000176	0.000706	CcSEcCtD
Bexarotene—Tension—Epirubicin—bone cancer	0.000175	0.000703	CcSEcCtD
Bexarotene—Dysgeusia—Epirubicin—bone cancer	0.000175	0.000702	CcSEcCtD
Bexarotene—Nervousness—Epirubicin—bone cancer	0.000174	0.000696	CcSEcCtD
Bexarotene—Back pain—Epirubicin—bone cancer	0.000173	0.000693	CcSEcCtD
Bexarotene—Angiopathy—Doxorubicin—bone cancer	0.000172	0.000691	CcSEcCtD
Bexarotene—Malaise—Methotrexate—bone cancer	0.000172	0.00069	CcSEcCtD
Bexarotene—Muscle spasms—Epirubicin—bone cancer	0.000172	0.000689	CcSEcCtD
Bexarotene—Vertigo—Methotrexate—bone cancer	0.000172	0.000688	CcSEcCtD
Bexarotene—Leukopenia—Methotrexate—bone cancer	0.000171	0.000685	CcSEcCtD
Bexarotene—Chills—Doxorubicin—bone cancer	0.00017	0.000683	CcSEcCtD
Bexarotene—RXRB—Gene Expression—EZH2—bone cancer	0.00017	0.00173	CbGpPWpGaD
Bexarotene—Arrhythmia—Doxorubicin—bone cancer	0.00017	0.00068	CcSEcCtD
Bexarotene—Nausea—Cisplatin—bone cancer	0.000169	0.000676	CcSEcCtD
Bexarotene—Alopecia—Doxorubicin—bone cancer	0.000168	0.000673	CcSEcCtD
Bexarotene—Cough—Methotrexate—bone cancer	0.000167	0.000668	CcSEcCtD
Bexarotene—Ill-defined disorder—Epirubicin—bone cancer	0.000166	0.000665	CcSEcCtD
Bexarotene—Malnutrition—Doxorubicin—bone cancer	0.000165	0.000663	CcSEcCtD
Bexarotene—Erythema—Doxorubicin—bone cancer	0.000165	0.000663	CcSEcCtD
Bexarotene—Anaemia—Epirubicin—bone cancer	0.000165	0.000662	CcSEcCtD
Bexarotene—Agitation—Epirubicin—bone cancer	0.000164	0.000658	CcSEcCtD
Bexarotene—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000163	0.00166	CbGpPWpGaD
Bexarotene—Flatulence—Doxorubicin—bone cancer	0.000163	0.000653	CcSEcCtD
Bexarotene—Myalgia—Methotrexate—bone cancer	0.000163	0.000652	CcSEcCtD
Bexarotene—Chest pain—Methotrexate—bone cancer	0.000163	0.000652	CcSEcCtD
Bexarotene—Arthralgia—Methotrexate—bone cancer	0.000163	0.000652	CcSEcCtD
Bexarotene—Tension—Doxorubicin—bone cancer	0.000162	0.000651	CcSEcCtD
Bexarotene—Dysgeusia—Doxorubicin—bone cancer	0.000162	0.000649	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000161	0.000647	CcSEcCtD
Bexarotene—Malaise—Epirubicin—bone cancer	0.000161	0.000646	CcSEcCtD
Bexarotene—Discomfort—Methotrexate—bone cancer	0.000161	0.000644	CcSEcCtD
Bexarotene—Nervousness—Doxorubicin—bone cancer	0.000161	0.000644	CcSEcCtD
Bexarotene—Vertigo—Epirubicin—bone cancer	0.000161	0.000644	CcSEcCtD
Bexarotene—Syncope—Epirubicin—bone cancer	0.00016	0.000643	CcSEcCtD
Bexarotene—Leukopenia—Epirubicin—bone cancer	0.00016	0.000641	CcSEcCtD
Bexarotene—Back pain—Doxorubicin—bone cancer	0.00016	0.000641	CcSEcCtD
Bexarotene—Muscle spasms—Doxorubicin—bone cancer	0.000159	0.000637	CcSEcCtD
Bexarotene—Palpitations—Epirubicin—bone cancer	0.000158	0.000633	CcSEcCtD
Bexarotene—Confusional state—Methotrexate—bone cancer	0.000157	0.00063	CcSEcCtD
Bexarotene—Loss of consciousness—Epirubicin—bone cancer	0.000157	0.00063	CcSEcCtD
Bexarotene—Cough—Epirubicin—bone cancer	0.000156	0.000625	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000155	0.00158	CbGpPWpGaD
Bexarotene—Infection—Methotrexate—bone cancer	0.000155	0.000621	CcSEcCtD
Bexarotene—Hypertension—Epirubicin—bone cancer	0.000154	0.000619	CcSEcCtD
Bexarotene—Ill-defined disorder—Doxorubicin—bone cancer	0.000153	0.000615	CcSEcCtD
Bexarotene—Nervous system disorder—Methotrexate—bone cancer	0.000153	0.000613	CcSEcCtD
Bexarotene—Anaemia—Doxorubicin—bone cancer	0.000153	0.000613	CcSEcCtD
Bexarotene—Thrombocytopenia—Methotrexate—bone cancer	0.000153	0.000612	CcSEcCtD
Bexarotene—Arthralgia—Epirubicin—bone cancer	0.000152	0.00061	CcSEcCtD
Bexarotene—Myalgia—Epirubicin—bone cancer	0.000152	0.00061	CcSEcCtD
Bexarotene—Chest pain—Epirubicin—bone cancer	0.000152	0.00061	CcSEcCtD
Bexarotene—Agitation—Doxorubicin—bone cancer	0.000152	0.000609	CcSEcCtD
Bexarotene—Anxiety—Epirubicin—bone cancer	0.000152	0.000608	CcSEcCtD
Bexarotene—Skin disorder—Methotrexate—bone cancer	0.000151	0.000607	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000151	0.000606	CcSEcCtD
Bexarotene—Hyperhidrosis—Methotrexate—bone cancer	0.000151	0.000604	CcSEcCtD
Bexarotene—Discomfort—Epirubicin—bone cancer	0.00015	0.000603	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.00015	0.00153	CbGpPWpGaD
Bexarotene—Malaise—Doxorubicin—bone cancer	0.000149	0.000598	CcSEcCtD
Bexarotene—Dry mouth—Epirubicin—bone cancer	0.000149	0.000597	CcSEcCtD
Bexarotene—Vertigo—Doxorubicin—bone cancer	0.000149	0.000596	CcSEcCtD
Bexarotene—Anorexia—Methotrexate—bone cancer	0.000149	0.000596	CcSEcCtD
Bexarotene—Syncope—Doxorubicin—bone cancer	0.000148	0.000595	CcSEcCtD
Bexarotene—Leukopenia—Doxorubicin—bone cancer	0.000148	0.000593	CcSEcCtD
Bexarotene—Confusional state—Epirubicin—bone cancer	0.000147	0.00059	CcSEcCtD
Bexarotene—Palpitations—Doxorubicin—bone cancer	0.000146	0.000586	CcSEcCtD
Bexarotene—Oedema—Epirubicin—bone cancer	0.000146	0.000585	CcSEcCtD
Bexarotene—Loss of consciousness—Doxorubicin—bone cancer	0.000145	0.000583	CcSEcCtD
Bexarotene—Infection—Epirubicin—bone cancer	0.000145	0.000581	CcSEcCtD
Bexarotene—Cough—Doxorubicin—bone cancer	0.000144	0.000579	CcSEcCtD
Bexarotene—Shock—Epirubicin—bone cancer	0.000144	0.000575	CcSEcCtD
Bexarotene—Nervous system disorder—Epirubicin—bone cancer	0.000143	0.000573	CcSEcCtD
Bexarotene—Thrombocytopenia—Epirubicin—bone cancer	0.000143	0.000573	CcSEcCtD
Bexarotene—Hypertension—Doxorubicin—bone cancer	0.000143	0.000572	CcSEcCtD
Bexarotene—Tachycardia—Epirubicin—bone cancer	0.000142	0.000571	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000142	0.000569	CcSEcCtD
Bexarotene—Skin disorder—Epirubicin—bone cancer	0.000142	0.000568	CcSEcCtD
Bexarotene—Hyperhidrosis—Epirubicin—bone cancer	0.000141	0.000565	CcSEcCtD
Bexarotene—Insomnia—Methotrexate—bone cancer	0.000141	0.000565	CcSEcCtD
Bexarotene—Myalgia—Doxorubicin—bone cancer	0.000141	0.000564	CcSEcCtD
Bexarotene—Arthralgia—Doxorubicin—bone cancer	0.000141	0.000564	CcSEcCtD
Bexarotene—Chest pain—Doxorubicin—bone cancer	0.000141	0.000564	CcSEcCtD
Bexarotene—Anxiety—Doxorubicin—bone cancer	0.00014	0.000562	CcSEcCtD
Bexarotene—Paraesthesia—Methotrexate—bone cancer	0.00014	0.000561	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00014	0.000561	CcSEcCtD
Bexarotene—Discomfort—Doxorubicin—bone cancer	0.000139	0.000558	CcSEcCtD
Bexarotene—Anorexia—Epirubicin—bone cancer	0.000139	0.000557	CcSEcCtD
Bexarotene—Dyspnoea—Methotrexate—bone cancer	0.000139	0.000557	CcSEcCtD
Bexarotene—Somnolence—Methotrexate—bone cancer	0.000139	0.000556	CcSEcCtD
Bexarotene—RXRA—Gene Expression—NR1I2—bone cancer	0.000138	0.00141	CbGpPWpGaD
Bexarotene—Dry mouth—Doxorubicin—bone cancer	0.000138	0.000552	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000137	0.0014	CbGpPWpGaD
Bexarotene—Dyspepsia—Methotrexate—bone cancer	0.000137	0.00055	CcSEcCtD
Bexarotene—Confusional state—Doxorubicin—bone cancer	0.000136	0.000546	CcSEcCtD
Bexarotene—Decreased appetite—Methotrexate—bone cancer	0.000136	0.000543	CcSEcCtD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000135	0.00138	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000135	0.00138	CbGpPWpGaD
Bexarotene—Oedema—Doxorubicin—bone cancer	0.000135	0.000541	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Methotrexate—bone cancer	0.000135	0.000539	CcSEcCtD
Bexarotene—Fatigue—Methotrexate—bone cancer	0.000134	0.000539	CcSEcCtD
Bexarotene—Infection—Doxorubicin—bone cancer	0.000134	0.000538	CcSEcCtD
Bexarotene—Pain—Methotrexate—bone cancer	0.000133	0.000534	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000133	0.000533	CcSEcCtD
Bexarotene—Shock—Doxorubicin—bone cancer	0.000133	0.000532	CcSEcCtD
Bexarotene—Nervous system disorder—Doxorubicin—bone cancer	0.000132	0.000531	CcSEcCtD
Bexarotene—Thrombocytopenia—Doxorubicin—bone cancer	0.000132	0.00053	CcSEcCtD
Bexarotene—Insomnia—Epirubicin—bone cancer	0.000132	0.000529	CcSEcCtD
Bexarotene—Tachycardia—Doxorubicin—bone cancer	0.000132	0.000528	CcSEcCtD
Bexarotene—Skin disorder—Doxorubicin—bone cancer	0.000131	0.000526	CcSEcCtD
Bexarotene—Paraesthesia—Epirubicin—bone cancer	0.000131	0.000525	CcSEcCtD
Bexarotene—Hyperhidrosis—Doxorubicin—bone cancer	0.00013	0.000523	CcSEcCtD
Bexarotene—Dyspnoea—Epirubicin—bone cancer	0.00013	0.000521	CcSEcCtD
Bexarotene—Somnolence—Epirubicin—bone cancer	0.00013	0.00052	CcSEcCtD
Bexarotene—Anorexia—Doxorubicin—bone cancer	0.000129	0.000516	CcSEcCtD
Bexarotene—Feeling abnormal—Methotrexate—bone cancer	0.000128	0.000515	CcSEcCtD
Bexarotene—Dyspepsia—Epirubicin—bone cancer	0.000128	0.000515	CcSEcCtD
Bexarotene—Gastrointestinal pain—Methotrexate—bone cancer	0.000127	0.000511	CcSEcCtD
Bexarotene—Decreased appetite—Epirubicin—bone cancer	0.000127	0.000508	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Epirubicin—bone cancer	0.000126	0.000505	CcSEcCtD
Bexarotene—Fatigue—Epirubicin—bone cancer	0.000126	0.000504	CcSEcCtD
Bexarotene—Pain—Epirubicin—bone cancer	0.000125	0.0005	CcSEcCtD
Bexarotene—Constipation—Epirubicin—bone cancer	0.000125	0.0005	CcSEcCtD
Bexarotene—Body temperature increased—Methotrexate—bone cancer	0.000123	0.000494	CcSEcCtD
Bexarotene—Abdominal pain—Methotrexate—bone cancer	0.000123	0.000494	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000123	0.000493	CcSEcCtD
Bexarotene—Insomnia—Doxorubicin—bone cancer	0.000122	0.000489	CcSEcCtD
Bexarotene—Paraesthesia—Doxorubicin—bone cancer	0.000121	0.000486	CcSEcCtD
Bexarotene—Dyspnoea—Doxorubicin—bone cancer	0.00012	0.000482	CcSEcCtD
Bexarotene—Feeling abnormal—Epirubicin—bone cancer	0.00012	0.000482	CcSEcCtD
Bexarotene—Somnolence—Doxorubicin—bone cancer	0.00012	0.000481	CcSEcCtD
Bexarotene—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000119	0.00122	CbGpPWpGaD
Bexarotene—Gastrointestinal pain—Epirubicin—bone cancer	0.000119	0.000478	CcSEcCtD
Bexarotene—Dyspepsia—Doxorubicin—bone cancer	0.000119	0.000476	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000117	0.0012	CbGpPWpGaD
Bexarotene—Decreased appetite—Doxorubicin—bone cancer	0.000117	0.00047	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000117	0.000467	CcSEcCtD
Bexarotene—Fatigue—Doxorubicin—bone cancer	0.000116	0.000467	CcSEcCtD
Bexarotene—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000116	0.00118	CbGpPWpGaD
Bexarotene—Pain—Doxorubicin—bone cancer	0.000115	0.000463	CcSEcCtD
Bexarotene—Constipation—Doxorubicin—bone cancer	0.000115	0.000463	CcSEcCtD
Bexarotene—Abdominal pain—Epirubicin—bone cancer	0.000115	0.000462	CcSEcCtD
Bexarotene—Body temperature increased—Epirubicin—bone cancer	0.000115	0.000462	CcSEcCtD
Bexarotene—Hypersensitivity—Methotrexate—bone cancer	0.000115	0.00046	CcSEcCtD
Bexarotene—Asthenia—Methotrexate—bone cancer	0.000112	0.000448	CcSEcCtD
Bexarotene—Feeling abnormal—Doxorubicin—bone cancer	0.000111	0.000446	CcSEcCtD
Bexarotene—Gastrointestinal pain—Doxorubicin—bone cancer	0.00011	0.000442	CcSEcCtD
Bexarotene—Pruritus—Methotrexate—bone cancer	0.00011	0.000442	CcSEcCtD
Bexarotene—Hypersensitivity—Epirubicin—bone cancer	0.000107	0.000431	CcSEcCtD
Bexarotene—Abdominal pain—Doxorubicin—bone cancer	0.000107	0.000428	CcSEcCtD
Bexarotene—Body temperature increased—Doxorubicin—bone cancer	0.000107	0.000428	CcSEcCtD
Bexarotene—Diarrhoea—Methotrexate—bone cancer	0.000107	0.000428	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000106	0.00108	CbGpPWpGaD
Bexarotene—Asthenia—Epirubicin—bone cancer	0.000105	0.00042	CcSEcCtD
Bexarotene—Pruritus—Epirubicin—bone cancer	0.000103	0.000414	CcSEcCtD
Bexarotene—Dizziness—Methotrexate—bone cancer	0.000103	0.000413	CcSEcCtD
Bexarotene—RXRA—Gene Expression—EIF2S1—bone cancer	0.000102	0.00104	CbGpPWpGaD
Bexarotene—Diarrhoea—Epirubicin—bone cancer	9.98e-05	0.0004	CcSEcCtD
Bexarotene—Hypersensitivity—Doxorubicin—bone cancer	9.94e-05	0.000399	CcSEcCtD
Bexarotene—Vomiting—Methotrexate—bone cancer	9.91e-05	0.000397	CcSEcCtD
Bexarotene—Rash—Methotrexate—bone cancer	9.83e-05	0.000394	CcSEcCtD
Bexarotene—Dermatitis—Methotrexate—bone cancer	9.82e-05	0.000394	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—MET—bone cancer	9.8e-05	0.000998	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—CDK4—bone cancer	9.8e-05	0.000998	CbGpPWpGaD
Bexarotene—Headache—Methotrexate—bone cancer	9.76e-05	0.000391	CcSEcCtD
Bexarotene—Asthenia—Doxorubicin—bone cancer	9.68e-05	0.000388	CcSEcCtD
Bexarotene—Dizziness—Epirubicin—bone cancer	9.65e-05	0.000387	CcSEcCtD
Bexarotene—Pruritus—Doxorubicin—bone cancer	9.55e-05	0.000383	CcSEcCtD
Bexarotene—Vomiting—Epirubicin—bone cancer	9.27e-05	0.000372	CcSEcCtD
Bexarotene—Nausea—Methotrexate—bone cancer	9.26e-05	0.000371	CcSEcCtD
Bexarotene—Diarrhoea—Doxorubicin—bone cancer	9.23e-05	0.00037	CcSEcCtD
Bexarotene—Rash—Epirubicin—bone cancer	9.2e-05	0.000369	CcSEcCtD
Bexarotene—Dermatitis—Epirubicin—bone cancer	9.19e-05	0.000368	CcSEcCtD
Bexarotene—Headache—Epirubicin—bone cancer	9.14e-05	0.000366	CcSEcCtD
Bexarotene—Dizziness—Doxorubicin—bone cancer	8.93e-05	0.000358	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	8.92e-05	0.000908	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—EZH2—bone cancer	8.88e-05	0.000904	CbGpPWpGaD
Bexarotene—Nausea—Epirubicin—bone cancer	8.66e-05	0.000347	CcSEcCtD
Bexarotene—Vomiting—Doxorubicin—bone cancer	8.58e-05	0.000344	CcSEcCtD
Bexarotene—Rash—Doxorubicin—bone cancer	8.51e-05	0.000341	CcSEcCtD
Bexarotene—Dermatitis—Doxorubicin—bone cancer	8.5e-05	0.000341	CcSEcCtD
Bexarotene—Headache—Doxorubicin—bone cancer	8.46e-05	0.000339	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—NDUFA12—bone cancer	8.23e-05	0.000838	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—MMP2—bone cancer	8.17e-05	0.000832	CbGpPWpGaD
Bexarotene—Nausea—Doxorubicin—bone cancer	8.02e-05	0.000321	CcSEcCtD
Bexarotene—RXRA—Metabolism—ENO2—bone cancer	8e-05	0.000814	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—GSTP1—bone cancer	7.74e-05	0.000788	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	7.64e-05	0.000777	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—DHFR—bone cancer	7.42e-05	0.000755	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GNA11—bone cancer	6.93e-05	0.000706	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NT5C3A—bone cancer	6.82e-05	0.000694	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CYP3A4—bone cancer	6.29e-05	0.00064	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.26e-05	0.000637	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—MMP9—bone cancer	6.14e-05	0.000626	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NDUFA12—bone cancer	5.43e-05	0.000552	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GSTP1—bone cancer	5.38e-05	0.000547	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—EGFR—bone cancer	4.96e-05	0.000505	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NT5C3A—bone cancer	4.5e-05	0.000458	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ENO2—bone cancer	2.99e-05	0.000304	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PTGS2—bone cancer	2.79e-05	0.000284	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—DHFR—bone cancer	2.77e-05	0.000282	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GNA11—bone cancer	2.59e-05	0.000264	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYP3A4—bone cancer	2.35e-05	0.000239	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.34e-05	0.000238	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GSTP1—bone cancer	2.01e-05	0.000204	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ENO2—bone cancer	1.97e-05	0.0002	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—DHFR—bone cancer	1.83e-05	0.000186	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GNA11—bone cancer	1.71e-05	0.000174	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTP1—bone cancer	1.32e-05	0.000135	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PTGS2—bone cancer	1.04e-05	0.000106	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PTGS2—bone cancer	6.86e-06	6.98e-05	CbGpPWpGaD
